1. Generics Bulletin
  2. >>Legal & IP

AbbVie Humira Lawsuit Withstands Alvotech Attack

Attempt Fails To Dismiss Adalimumab Litigation Ahead Of FDA Decision On AVT02 Biosimilar

 
• By Dave Wallace

Alvotech has failed in an attempt to dismiss US litigation initiated by AbbVie over Alvotech’s AVT02 proposed rival to higher-strength Humira. The company is expecting an FDA decision on the adalimumab biosimilar this month.

Blue Button Dismiss
Alvotech had attempted to have the litigation dismissed • Source: Alamy

Alvotech’s attempt to have a US court dismiss patent litigation initiated by AbbVie over Humira (adalimumab) has fallen on deaf ears, with an Illinois district court rejecting the biosimilars firm’s arguments that the originator had sued the wrong Alvotech entity and that the venue was improper.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

Sandoz Admits To Widescale Infringement In Resolving US Rinvoq Patent Tussle

 
• By Dean Rudge

Sandoz has reached an agreement with AbbVie to dismiss without prejudice patent-infringement litigation involving more than 20 patents shielding the originator’s blockbuster JAK inhibitor Rinvoq.

Biocon Chooses To Settle Over Eylea In US – Will Others Follow?

 
• By Dave Wallace

After Amgen’s surprise launch of the first US biosimilar to Eylea last year, expectations around competition are being further upended with the news that Biocon Biologics has struck a settlement deal with Regeneron allowing it to launch its own aflibercept rival in the second half of 2026. Will other challengers follow suit?

Sandoz Attacks Amgen Over US Enbrel Exclusivity

 
• By Dave Wallace

Having failed in US patent litigation over Amgen’s Enbrel, Sandoz is taking an alternative approach in trying to get its Erelzi biosimilar to market in the US ahead of patent expiry in 2029: launching an antitrust attack against the originator for “unlawfully extending and entrenching its monopoly."

Jazz Agrees To Fork Out $145m To Resolve Most Xyrem ‘Pay-For-Delay’ Claims

 
• By Dean Rudge

Jazz has agreed a nine figure settlement agreement in the US with purchasers of its Xyrem blockbuster following claims that it illegally delayed generic competition to the blockbuster treatment for narcolepsy via patent-litigation settlement agreements with several ANDA sponsors.

More from Generics Bulletin